Advances in the treatment of acute myelogenous leukemia.
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006470:Hemorrhage / Q000209:etiology / Q000628:therapy; D006801:Humans; D007167:Immunotherapy; D007239:Infections / Q000209:etiology / Q000628:therapy; D007945:Leukemia, Lymphoid / Q000139:chemically induced / Q000150:complications / Q000209:etiology; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000628:therapy*; D007953:Leukemia, Radiation-Induced / Q000209:etiology; D008577:Meningeal Neoplasms / Q000628:therapy; D011289:Preleukemia / Q000175:diagnosis; D011379:Prognosis; D012075:Remission, Spontaneous; D014184:Transplantation, Homologous
D000970:Antineoplastic Agents; D003561:Cytarabine; D003630:Daunorubicin